These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Diagnostic performance of anti-cyclic citrullinated antibodies and IgM rheumatoid factor in rheumatoid arthritis].
    Author: Lemos A, Ramos MP, Furtado MJ, Carvalho C, Santos MJ, Silva JC, Ventura H.
    Journal: Acta Reumatol Port; 2007; 32(4):345-9. PubMed ID: 18159201.
    Abstract:
    UNLABELLED: The presence of IgM class rheumatoid factor RF-M in the serum is one of the ACR criteria for the classification of rheumatoid arthritis RA . OBJECTIVES: To compare the sensitivity and specificity of two diagnostic markers for RA in Portuguese patients the 2nd generation anti-cyclic citrullinated peptide antibodies anti-CCP2 and the RF-M. METHODS: Serum samples from 56 patients with established RA 44 women and 12 men mean disease duration 9 5 -8 5 years were evaluated for the presence of anti-CCP2 and RF-M. Results were compared with 93 samples from a control group with identical demographic characteristics 43 from patients with spondylarthropaties and 50 from healthy blood donors . The determination of anti-CCP2 antibodies was performed by enzymatic fluroimunoassay and RF-M was measured by microElisa. RESULTS: Anti-CCP2 antibodies were positive in 40 patients with RA 71 4 at a mean antibody concentration of 350 5 UA ml range 11-1670 UA ml and negative in all controls. The RF-M was positive in 34 patients with RA 60 7 in 4 patients with spondylarthropaties 9 3 and in one blood donor 2 . The sensitivity specificity positive predictive value and negative predictive value for RF-M was 60 7 90 7 89 5 and 63 9 and for anti-CCP2 was 71 4 100 100 and 72 9 respectively. CONCLUSIONS: The anti-CCP2 assay showed an excellent specificity and a global performance superior to that of the RF-M test in this population with established RA.
    [Abstract] [Full Text] [Related] [New Search]